TRVI News and Press, Trevi Therapeutics Inc. From 09/22/22

Trevi Therapeutics Announces Proposed Public Offering PR Newswire NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio!...

Clinical-stage biopharma, Trevi Therapeutics, Inc. ( NASDAQ: TRVI ) gained 19% pre-market Monday after the company announced complete data from its Phase 2 trial for lead asset Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) U.K.-based CAN...

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis PR Newswire Data from full set of subjects was statistically significant for the primary ef...

Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fib...

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire Presentation will be held on Monday, September 12, 2022 , from 10:30 a.m. to 11:00 a.m. EDT NEW HAVEN, Conn. , Sept. 7, 2022 /PRNewswire/...

Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 PR Newswire The event will feature presentations from experts Dr. Peter Dicpinigaitis , MD, and Dr. Brian Kim , MD, MTR...

Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release PR Newswire Late-breaker abstract accepted for oral presentation on the interim analysis of cough in pa...

Phoenix, Arizona--(Newsfile Corp. - August 22, 2022) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER)...

Trevi Therapeutics, Inc. (TRVI) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Offi...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...